Retatrutide

Research Peptide

Also known as: LY3437943

What is Retatrutide?

Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) showing unprecedented weight loss results in clinical trials.

How It Works

Retatrutide activates three receptors: GIP, GLP-1, and glucagon, providing synergistic effects on appetite, glucose metabolism, and energy expenditure.

What Research Shows

Animal Studies

Human Studies

Key Findings:

Up to 24% body weight loss in trials
Triple receptor agonism
Currently in Phase 3 clinical trials

Limited Human Research

Most research on Retatrutide has been conducted in animal models. Human clinical trials are limited or absent. Results may not translate directly to humans.

Dosing Protocol

Typical Dose

1-12 mg

Frequency

Once weekly

Route

Subcutaneous injection

Duration

Ongoing (investigational)

These are general guidelines based on research literature and community protocols. Individual dosing should be determined by a qualified healthcare provider.

Safety & Risks

Reported Side Effects:

NauseaDiarrheaVomitingConstipation

Contraindications:

Pregnancy
Not yet FDA-approved

Important: This information is for research purposes only. Always consult with a qualified healthcare provider before using any peptide. Never use peptides without proper medical supervision.

Sourcing & Quality

Quality varies significantly between peptide sources. When sourcing Retatrutide, consider:

Third-party testing (HPLC, Mass Spectrometry)
Certificate of Analysis (CoA) availability
Purity levels (>98% recommended)
Beware of LPS (endotoxin) contamination

CalcPep does not sell peptides or recommend specific vendors. Always verify product quality through independent testing.

Quick Facts

Track Your Protocol

Use CalcPep to calculate doses, log injections, and track your progress.

Get CalcPep